

Proposal for re-election of the current members of the Board of Directors:

**Claus Bjerre**

Born:1971

Nationality: Danish

Education and professional experience: Claus holds an M.Sc. from Copenhagen Business School, Denmark, and an MBA in Strategy and Finance from the UCLA Anderson School of Management. He was CEO of Atos Medical from early 2014 through to the end of 2018. Atos Medical was sold by EQT to PAI Partners during his tenure as CEO in 2016. Claus has held numerous senior leadership positions in Coloplast A/S, a Danish global consumable Medtech company, most recently as President - North America, Japan, and Australia. Before joining Coloplast, Claus spent 10 years within corporate strategy, mergers and acquisitions, and private equity across industries working for McKinsey & Company, Nordic Capital, and Mattel.

Other current engagement: Claus is currently Senior Advisor to KKR & Co. Inc., Chairman of the Board of directors in Clinisupplies Ltd, and Managing Director of Eden Invest LLC.

Shareholding in Sedana Medical: 0 shares.

Independent in relation to the company, its management, and the company's major shareholders.

**Hilde Furberg**

Born:1958

Nationality: Norwegian

Education and professional experience: Hilde Furberg has a M.Sc. in Chemistry from Oslo University, Norway. Hilde is an independent consultant and professional Board member. She has extensive leadership experience from over 35 years in sales, marketing, strategy, and management within Pharma/Biotech, from both small and large global companies. Hilde has worked operationally in companies such as Genzyme and Baxter, most recently as Senior Vice President EMEA Rare Diseases at Sanofi Genzyme. In addition, Hilde has experience from positions as Board member in BerGenBio, Probi, Pronova, Clavis, Algeta, Tappin, and CombiGene and as Chairman of the Board of directors in Blueprint Genetics.

Other current engagement: Industrial Advisor to Investinor, and Board member in PCI Biotech, Calliditas Therapeutics, Bio-Me, Herantis, and Pluvia Biotech.

Shareholding in Sedana Medical:4,500 shares.

Independent in relation to the Company and its management and in relation to major shareholders.

## **Christoffer Rosenblad**

Born: 1975

Nationality: Swedish

Education and professional experience: Christoffer holds an M.Sc. from Chalmers University of Technology and a master's degree in economics from the School of Business and Economics at the University of Gothenburg, Sweden. He held positions as Chief Operating Officer and Chief Financial Officer of XVIVO Perfusion AB. He has also led XVIVO's North American operations and resided in the United States. He has held leading positions in finance and strategic management at Novartis and LG Electronics.

Other current engagement: CEO at XVIVO Perfusion AB.

Shareholding in Sedana Medical: 10,000 shares.

Independent in relation to the company, its management, and the company's major shareholders.

Proposal for election of a new member of the Board of Directors

## **Jens Viebke**

Born: 1967

Nationality: Swedish

Education and professional experience: Jens Viebke has a PhD in Polymer Technology from the Royal Institute of Technology of Stockholm and holds an Executive MBA from the Stockholm School of Economics, Sweden. He has held positions as President of Acute Care Therapies and also as the President of the Critical Care and Vascular Systems divisions in the Medical Systems business area at Getinge AB. He has long and broad experience in the healthcare industry and has previously held positions in research and development, as well as strategy and marketing, at large companies in the healthcare industry, including GE Healthcare and Pharmacia & Upjohn.

Other current engagement: Executive Vice President Corporate Development at Getinge AB

Shareholding in Sedana Medical: 0 shares.

Independent in relation to the company, its management, and the company's major shareholders.

**Donna Haire**

Born: 1969

Nationality: American

Education and professional experience: Donna Haire has an M.S. in Biology from Cleveland State University and a B.S. in Biology from the University of Akron, USA. She is an executive with over 30 years of experience in healthcare, pharmaceutical, and medical device industries. Donna has held positions as Executive Vice President at On Target Laboratories, Vice President, Head of Medical Care Global Regulatory Affairs at Bayer, Senior Vice President of Regulatory, Quality, Clinical, and Medical Affairs at AngioDynamics and has held senior level positions at Philips Healthcare and Medtronic. Donna was an Adjunct Professor at the University of Akron School of Law. She served as an AdvaMed Technical and Regulatory Board Committee Member. Donna was designated a U.S. regulatory expert to lead multiple international trade negotiations in regulatory convergence.

Other current engagement: CEO of The Eriah Group, Inc

Shareholding in Sedana Medical: 0 shares.

Independent in relation to the company, its management, and the company's major shareholders.